MOVEMENT DISORDERS Journal
Overview
publication venue for
- A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease 2023
- Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden 2023
- A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson's Disease. 32:783-789. 2017
- Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long-term dyskinesia reduction. 9:409-414. 1994
- Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson's disease (PD): A pooled analysis of 4 studies 2020
- 24-hour Efficacy Profile of Rotigotine in Patients with Advanced Parkinson's Disease: A Post-hoc Analysis. 2014
- Identification of Physical, Cognitive, and Affective Variables that Relate to Falls in Parkinson's Disease 2010
Research
category
- CLINICAL NEUROLOGY Category
Identity
International Standard Serial Number (ISSN)
- 0885-3185
Electronic International Standard Serial Number (EISSN)
- 1531-8257
Other
journal abbreviation
- MOVEMENT DISORD